Insider buying last 90 days
No open-market insider purchases were filed for ARWR in the last 90 days.
From Form 4 filings, dated to when each was filed.
Every ARWR insider filing, plotted on the chart in Gekko.Open ARWR in Gekko
NASDAQ: ARWR
Arrowhead Pharmaceuticals (ARWR) Stock Analysis & Forecast
Sep 28 close
$65.46−0.46 (−0.7%)
Gekko Brief
Arrowhead Pharmaceuticals closed at $65.46 on 28 September 2026, -0.7% on the day. The price sits between the 50-day ($82.03) and 200-day ($72.57) moving averages, inside a 52-week range of $31.46 to $95.49. The GekkoIndex reads 68.7, in the Accumulation zone, down 8.3 points over five sessions. Gekko Fair Value is $93.20, so the price is 29.8% below it.
The next earnings report is due on 24 November 2026, 56 days away (after close). Over the last 8 reports the company beat the earnings estimate 3 times, with an average move of 13.6% across the report. Over the last 30 days there were 2 unusual options signals. Seasonally, the next 20 trading days from this point averaged +2.6% over the last 5 years, rising in 3 of them.
12 firms rate the stock: 11 buy, 1 hold and 0 sell, with a consensus target of $110.00. A typical daily move is about 6.6%, and a typical 20-day move about 10.7%. On the swing-trade checklist, 4 items read supportive and 1 reads as a headwind (smart money).
Generated Sep 29, 2026 from the data above.
Arrowhead Pharmaceuticals price vs fair value
Close $65.46200-day averageGekko Fair Value $93.20
Arrowhead Pharmaceuticals quick facts
- Market cap
- $9.22B
- P/E ratio
- —
- Forward P/E
- 111.1
- EPS, TTM
- −$2.38
- Revenue, TTM
- $669.5M
- Profit margin
- -47.8%
- Dividend yield
- —
- Beta
- 1.28
- Volume
- 1.50M avg 2.19M
- 1-year return
- +106.8%
- Typical daily move
- ±6.6%
- Typical 20-day move
- ±10.7%
- 50-day average
- $82.03
- 200-day average
- $72.57
- Next earnings
- Nov 24 after close
- Shares outstanding
- 141.3M
Arrowhead Pharmaceuticals swing-trade checklist
Arrowhead Pharmaceuticals scores 4 supportive, 1 mixed and 1 headwind across the 6 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
4 supportive1 mixed1 headwind
- Trendmixed
Averages disagree
Close $65.46 sits between the 50-day ($82.03) and 200-day ($72.57) averages, or the averages disagree.
See the chart - GekkoIndexsupportive
68.7, Accumulation
Reading 68.7 is in the Accumulation zone.
See the GekkoIndex - Fair valuesupportive
29.8% below
Price is 29.8% below Gekko Fair Value (more than 5% below).
See fair value - Smart moneyheadwind
Leans bearish
Last 30 days: 2 unusual options signals.
See smart money - Earnings risksupportive
Reports in 56 days
Next report Nov 24, 2026, 56 days away — outside a typical 20-trading-day hold.
See earnings - Seasonalitysupportive
+2.6% on average
From this point in the calendar, the next 20 trading days averaged +2.6% over 5 years, rising in 3 of them.
See seasonality
A description of current data, not a recommendation. How this page works
Arrowhead Pharmaceuticals stock chart and price history
Arrowhead Pharmaceuticals closed at $65.46 on Sep 28, 2026, +106.8% over the past year, inside a 52-week range of $31.46 to $95.49.
Close50-day average200-day averageVolume
Use the left and right arrow keys to read daily values.
Performance Breakdown
- 1 month
- −26.1%
- 3 months
- −18.7%
- 6 months
- +13.3%
- 1 year
- +106.8%
The full ARWR chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open ARWR in Gekko
Follow Arrowhead Pharmaceuticals through every session
Put ARWR on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Track ARWR in GekkoFree for 7 days. No credit card required.
About Arrowhead Pharmaceuticals
Arrowhead Pharmaceuticals works on medicines for serious and hard-to-treat conditions, built around RNA interference technology that aims to switch off disease-causing genes. Its pipeline spans liver conditions linked to alpha-1 antitrypsin deficiency, high triglyceride levels, cholesterol-related targets, kidney cancer, lung and airway disorders, muscular dystrophy, gout and COVID-19-related pulmonary illness, with programs at stages ranging from early clinical trials to later-phase testing.
Much of its work is carried out through partnerships as well as internal research. It has agreements with Janssen Pharmaceuticals to jointly develop a set of RNAi candidates aimed at liver-related targets, and with Takeda Pharmaceuticals U.S.A. on another liver-disease therapeutic. It also contributes to programs such as a subcutaneous treatment for chronic hepatitis B, a candidate aimed at lowering apolipoprotein levels, and cardiovascular-focused therapies developed alongside outside partners, reflecting a model that combines its own science with outside collaboration.
Arrowhead Pharmaceuticals is based in Pasadena, California, and traces its founding back to 1989. Its shares are listed on the NASDAQ under the ticker ARWR.
- Listed
- NASDAQ
- Sector
- Health technology
- Industry
- Biotechnology
- Website
- arrowheadpharma.com
Arrowhead Pharmaceuticals GekkoIndex: the smart money zone
Arrowhead Pharmaceuticals’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 68.7, in the Accumulation zone, down 8.3 points over five sessions.
68.7Accumulation
Down 8.3 points over five sessions, from the Buying zone.
Reading for Sep 28, 2026
What followed past readings in each zone
| Zone | Readings | 5 days | 20 days | ||
|---|---|---|---|---|---|
| Buying | 47 | +0.4% | −0.3% | ||
| Accumulation (current zone) | 210 | +0.6% | +1.1% | ||
| Neutral | 378 | +1.1% | +6.0% | ||
| Distribution | 36 | +2.5% | +12.3% | ||
| Selling | 1 | Too few readings yet | |||
Average ARWR share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Accumulation readings averaged +2.3% over 20 days. Past behaviour doesn’t guarantee future results.
Accumulation zone: Institutional interest building. About the five zones →
See every daily GekkoIndex reading plotted over the ARWR price, zone by zone.Track ARWR in Gekko
Is Arrowhead Pharmaceuticals stock overvalued? Gekko Fair Value
Arrowhead Pharmaceuticals trades 29.8% below Gekko Fair Value of $93.20, so the shares are undervalued on Gekko’s estimate.
Gekko’s own estimate of what Arrowhead Pharmaceuticals shares are worth, recalculated every trading day.
$93.20
Gekko Fair Value, Sep 24, 2026
29.8% Undervalued
Gekko Fair Value on every chart, with the gap to price updating daily.Open ARWR in Gekko
Arrowhead Pharmaceuticals insider and Congress trading
No open-market insider purchases were filed for Arrowhead Pharmaceuticals, and no Congress trades were disclosed, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
Congress trades last 90 days
No trades in ARWR were disclosed by members of Congress in the last 90 days.
From congressional disclosures, which report amounts as ranges.
Congress disclosures for ARWR, plotted on the chart in Gekko.Open ARWR in Gekko
Unusual options activity last 30 days
2signals, 34% of the flagged premium in calls.
Latest: Bullish flow on Sep 17, $374K in unusual premium.
Hedge funds and billionaires quarter ended Mar 31
1of the funds Gekko tracks holds ARWR.
0added0opened1trimmed1sold out
Every signal with its contract, strike and premium, and which funds are on each side.Unlock in Gekko
Arrowhead Pharmaceuticals earnings: next date and track record
Arrowhead Pharmaceuticals reports on Nov 24, 2026, after the close (56 days away), and beat the EPS estimate in 3 of its last 8 reports.
Next earnings report
Nov 24, 2026
Expected after the close, 56 days away
- EPS estimate
- −$1.59
- Revenue estimate
- $59.19M
3 of 8reports beat the EPS estimate
±13.6%average move across the report
5 of 8reports followed by a gain
Share-price move across each report
Last earnings call, Aug 4, 2026 AI summary
- What they said
- Arrowhead reported positive Phase III results from SHASTA-3 and SHASTA-4 trials for plozasiran in severe hypertriglyceridemia (sHTG), meeting all primary and secondary endpoints with median triglyceride reductions of 79-81%. Acute pancreatitis events were reduced 78% versus placebo in the broad sHTG population, and 100% in the highest-risk subgroup. The company acquired a priority review voucher to accelerate FDA review from 10 to 6 months, with sNDA submission planned before end of 2026.
- Guidance
- Arrowhead plans to submit an sNDA to the FDA before end of 2026, followed by additional global filings. The priority review voucher could accelerate approval timeline by 4 months. Management views sHTG as a substantially larger commercial opportunity than the existing FCS indication.
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Aug 4, 2026 | −$1.36 est −$1.23 | $75.25M est $44.17M | +1.0% |
| May 7, 2026 | −$0.93 est −$1.11 | $73.74M est $73.84M | −8.2% |
| Feb 5, 2026 | $0.22 est −$0.37 | $264.0M est $213.9M | −5.2% |
| Nov 25, 2025 | −$0.18 est −$0.11 | $256.5M est $175.3M | +30.4% |
| Aug 7, 2025 | −$1.26 est −$0.94 | $27.77M est $154.1M | +0.7% |
| May 12, 2025 | $2.75 est −$0.46 | $542.7M est $116.3M | +17.3% |
| Feb 10, 2025 | −$1.39 est −$0.72 | $2.50M est $19.05M | −6.7% |
| Nov 26, 2024 | −$1.37 est −$0.92 | $3.55M est $55.07M | +39.2% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
Arrowhead Pharmaceuticals stock forecast and analyst price targets
Analysts’ average 12-month price target for Arrowhead Pharmaceuticals is $110.00, +68.0% from the last close, from 12 firms rating the stock in the last 90 days.
$110.00consensus 12-month target, +68.0% from the last close
Now $65.46Avg $110.00
Low $74High $126
Each firm’s latest rating in the last 90 days: 12 firms.
Latest analyst actions
| Date | Firm | Target | vs price |
|---|---|---|---|
| Sep 24 | Goldman Sachs | $74 | +13.0% |
| Sep 21 | H.C. Wainwright | $120 | +83.3% |
| Sep 16 | Citi | — | — |
| Sep 15 | J.P. Morgan | — | — |
| Sep 8 | Citi | $108 | +65.0% |
+1.1%average 20-day move after past Accumulation readings
+2.6%average move over the next 20 trading days in the last 5 years
±6.6%typical daily move, from the 14-day average range
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
Arrowhead Pharmaceuticals seasonality: the next 20 trading days
Over the next 20 trading days from Sep 29, Arrowhead Pharmaceuticals averaged +2.6% across the last 5 years, rising in 3 of them.
Next 20 trading days, by year
Average move and hit rate
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | −0.6% | 2 of 5 |
| Next 10 trading days | +0.3% | 2 of 5 |
| Next 15 trading days | +4.9% | 3 of 5 |
| Next 20 trading days | +2.6% | 3 of 5 |
| Next 30 trading days | +12.1% | 5 of 5 |
For scale, ARWR’s typical 20-trading-day move in either direction is about 10.7%.
Arrowhead Pharmaceuticals market cap and key statistics
Arrowhead Pharmaceuticals’s market cap is $9.22B and revenue of $669.5M over the last twelve months.
Valuation
- Market cap
- $9.22B
- Forward P/E
- 111.1
- EPS, TTM
- −$2.38
- Gekko Fair Value
- $93.20
Trading
- Volume
- 1.50M
- Avg volume, 20 days
- 2.19M
- 52-week high
- $95.49
- 52-week low
- $31.46
- Shares outstanding
- 141.3M
Financials
- Revenue, TTM
- $669.5M
- Profit margin
- -47.8%
- Return on equity
- -55.2%
- Quarterly earnings growth, YoY
- +9.8%
Risk and income
- Beta
- 1.28
- Typical daily move
- ±6.6%
- Typical 20-day move
- ±10.7%
Arrowhead Pharmaceuticals stock news this week
1 headline about Arrowhead Pharmaceuticals from the past week, newest first, each linking to the publisher.
- Arrowhead Pharmaceuticals Drops 5.4% Amid Sector-Wide SellingAlphaStreet, Sep 23
Arrowhead Pharmaceuticals peers
Arrowhead Pharmaceuticals’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| AMGNAmgen | Neutral | 24.4% below |
| GILDGilead Sciences | Neutral | 6.9% above |
| MRNAModerna | Neutral | 73.2% above |
| NTRANatera | Distribution | 25.1% above |
| IQVIQVIA | Neutral | 14.2% above |
| UTHRUnited Therapeutics | Accumulation | 23.6% below |
A peer links to its own page where one exists.
Arrowhead Pharmaceuticals stock FAQ
What is Arrowhead Pharmaceuticals’s market cap?
Arrowhead Pharmaceuticals’s market cap is $9.22B at the Sep 28, 2026 close of $65.46, with 141.3M shares outstanding.
What is the Arrowhead Pharmaceuticals stock forecast?
The consensus analyst 12-month price target for Arrowhead Pharmaceuticals is $110.00, +68.0% from the last close. Of the 12 firms that rated the stock in the last 90 days, 11 rate it a buy, 1 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.
Is Arrowhead Pharmaceuticals stock overvalued or undervalued?
On Gekko’s estimate Arrowhead Pharmaceuticals is undervalued: the Sep 28, 2026 close of $65.46 is 29.8% below Gekko Fair Value of $93.20. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
When does Arrowhead Pharmaceuticals report earnings next?
Arrowhead Pharmaceuticals is expected to report on Nov 24, 2026, after the market closes (56 days away). Analysts expect earnings of −$1.59 per share on revenue of $59.19M. Arrowhead Pharmaceuticals beat the earnings estimate in 3 of its last 8 reports, moving 13.6% on average across the report.
What is Arrowhead Pharmaceuticals’s 52-week high and low?
Arrowhead Pharmaceuticals’s 52-week high is $95.49 and its 52-week low is $31.46; it closed at $65.46 on Sep 28, 2026, +106.8% over the past year.
Is Arrowhead Pharmaceuticals stock a buy right now?
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 4 of the 6 items with data read as supportive (gekkoindex, fair value, earnings risk and seasonality), 1 as mixed (trend) and 1 as a headwind (smart money). The checklist is a description of current data, not a recommendation.
Is there unusual options activity in Arrowhead Pharmaceuticals?
Gekko flagged 2 unusual options signals in Arrowhead Pharmaceuticals over the last 30 days, with $386K of flagged premium in calls and $752K in puts. The latest, bullish flow, was on Sep 17, 2026 with $374K in unusual premium. The signal-by-signal table is in Gekko.
How this page works
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
See Arrowhead Pharmaceuticals the way Gekko members do
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,380 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.